Meropenem Kabi (Meropenem Trihydrate)

• Meropenem is a broad‑spectrum carbapenem antibiotic indicated for serious infections affecting various organ systems.
• Complicated intra‑abdominal infections: provides rapid bacterial eradication in patients with intra‑abdominal sepsis.
• Complicated urinary tract infections: achieves effective clearance of resistant uropathogens in complicated UTIs.
• Nosocomial pneumonia: treats hospital‑acquired lung infections caused by multidrug‑resistant bacteria.
• Meningitis: penetrates the cerebrospinal fluid to eradicate causative organisms in bacterial meningitis.
• Severe sepsis and septic shock: offers potent bactericidal activity in patients with life‑threatening systemic infection.

• Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This blockade prevents cross‑linking of the cell wall, leading to osmotic instability, cell lysis and bacterial death. Its broad spectrum includes many Gram‑negative, Gram‑positive and anaerobic organisms, and it remains stable against most β‑lactamases, preserving its activity.

Meropenem may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate nausea during therapy.
• Diarrhea: loose stools, occasionally leading to dehydration.
• Infusion site phlebitis: pain or redness at the IV site.

Serious or Rare Side Effects

• Seizures: increased risk in patients with renal impairment or CNS disorders.
• Anaphylaxis: severe hypersensitivity reaction requiring immediate treatment.
• Clostridioides difficile‑associated diarrhea: may develop from disruption of normal gut flora.

When using Meropenem, several precautionary measures should be observed to minimize risk.

• Renal function: adjust dose in patients with impaired renal clearance.
• Allergy history: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams.
• Seizure risk: monitor closely in patients with pre‑existing CNS disorders.
• Pregnancy and lactation: use only if potential benefit justifies potential risk to fetus or infant.
• Concomitant nephrotoxic drugs: evaluate renal safety when combined with other nephrotoxic agents.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines; awareness of major and moderate interactions helps ensure safe therapy.

Major Interactions (Avoid)

• Valproic acid: may markedly reduce meropenem plasma concentrations, compromising efficacy.
• Seizure‑threshold agents (e.g., imipenem, quinolones): combined use can increase the risk of seizures.

Moderate Interactions (Monitor Closely)

• Diuretics: may affect renal excretion and require dose adjustment.
• Anticoagulants (warfarin): may alter INR, necessitating closer monitoring.
• Aminoglycosides: concurrent use can increase nephrotoxicity risk.